Harmon Cyrus 4
4 · Olema Pharmaceuticals, Inc. · Filed Sep 18, 2025
Insider Transaction Report
Form 4
Harmon Cyrus
Director
Transactions
- Sale
Common Stock
2025-09-18$8.32/sh−3,086$25,676→ 117,028 total(indirect: See Footnote) - Sale
Common Stock
2025-09-16$8.04/sh−10,000$80,400→ 754,140 total - Sale
Common Stock
2025-09-18$8.33/sh−10,000$83,300→ 744,140 total - Sale
Common Stock
2025-09-16$8.08/sh−1,914$15,465→ 120,114 total(indirect: See Footnote)
Footnotes (5)
- [F1]The weighted average sale price for the transaction reported was $8.04, and the range of prices was between $8.02 and $8.09. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.
- [F2]The weighted average sale price for the transaction reported was $8.33, and the range of prices was between $8.28 and $8.37. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.
- [F3]The weighted average sale price for the transaction reported was $8.08, and the range of prices was between $8.04 and $8.08. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.
- [F4]The shares are held by the Harmon Family Investors LLC, of which the Reporting Person is the manager.
- [F5]The weighted average sale price for the transaction reported was $8.32, and the range of prices was between $8.29 and $8.33. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.